CROSSing into New Therapies for Esophageal Cancer
Int J Radiat Oncol Biol Phys
.
2022 May 1;113(1):5-10.
doi: 10.1016/j.ijrobp.2021.12.177.
Authors
Michael H Buckstein
1
,
Christopher J Anker
2
,
Michael D Chuong
3
,
Maria A Hawkins
4
,
Jordan Kharofa
5
,
Jeffrey R Olsen
6
Affiliations
1
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
2
Division of Radiation Oncology, University of Vermont Larner College of Medicine, Burlington, Vermont.
3
Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida.
4
University College London, London, United Kingdom.
5
Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
6
Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: Jeffrey.R.Olsen@CUAnschutz.edu.
PMID:
35427559
DOI:
10.1016/j.ijrobp.2021.12.177
No abstract available
Publication types
Editorial
Comment
MeSH terms
Esophageal Neoplasms* / therapy
Humans